What is cutaquig?

Cutaquig is a treatment for adults with primary immunodeficiency (PI) disease1

Cutaquig is used to treat adults with Primary Immunodeficiency (PI) disease. There are many forms of PI. The most common types lead to an inability to make a very important kind of protein called antibodies, which protect your body against infections.1

As a ready-to-use liquid solution containing immunoglobulin G—also known as IgG—cutaquig is made from human plasma donated by healthy people.1,2 It contains the antibodies you may be missing.1 Regular use of cutaquig will help your body to fight bacteria and viruses that cause infections.1,2

Without antibodies, you’re at greater risk for infections caused by bacteria and viruses1

Cutaquig contains the antibodies you’re missing1

With regular administration, cutaquig helps your body fight bacteria and viruses that cause infections1

How to use cutaquig

Cutaquig is a subcutaneous immunoglobulin therapy (or SCIg).1 With SCIg, you infuse cutaquig under the skin instead of into a vein (infusing medication for PI into a vein is known as intravenous immunoglobulin therapy, or IVIg).1

Once you’ve been trained by your healthcare provider, you’ll have the option to self-administer cutaquig.1 Like most patients who choose to self-administer, you may gain a greater sense of freedom. Plus, cutaquig offers convenience—you’ll be able to self-administer almost anywhere, including home, work, school.3-5

With cutaquig therapy, there is a low rate of side effects—mostly local infusion site reactions, including but not limited to redness, swelling, and itching.1,6 In a clinical study, more than 99% of local reactions were mild or moderate.6 You may experience some of these, especially if you are newly starting SCIg therapy.5 Discuss any side effects you experience with your healthcare provider, who may be able to help you address them.1

Cutaquig offers proven safety and efficacy for adults with PI1

Zero Serious Bacterial Infections1,6

No hospitalizations due to infection in adult patients6

1 hospitalization in an adolescent patient due to respiratory synctial virus infection was reported in the total study population (n=61)

In a clinical study, adults taking cutaquig experienced a low rate of absences from work or school due to infection.3,4

The most common side effects are mild or moderate infusion site reactions, which usually go away within 24 hours.1

The IgCares program and its many benefits

Cutaquig is backed by the IgCares program, designed to inspire you with initiatives, including:

Care for your self

Infusion support, as well as
exclusive tools and educational information, make starting and managing therapy seamless

Care for your spirit

Personal connections
to peers, the PI community,
and Patient Educators

Care for your causes

Our charitable giving initiative
that benefits research and the PI community

Care for your world

Our advanced recycling service
that protects the environment while helping you safely dispose of infusion supplies

Care for yourself

Exclusive access
to educational and
informational services

Care for your spirit

Personal connections
to peers, the PI community,
and patient advocates

Care for your causes

A special initiative
that lets you help support
the PI community

Care for your world

A safety and sustainability
service
that transforms your
infusion supplies into energy

The IgCares program is complimentary.

IgCares Patient Support Program

Join IgCares and start enjoying all the features and benefits of Octapharma’s robust patient support program.

References:
  1. Cutaquig® [package insert]. Lachen, Switzerland: Octapharma AG; 2019.
  2. Clinical Study Report SCGAM-01. Clinical Phase 3 study to evaluate the pharmacokinetics, efficacy, tolerability and safety of subcutaneous human immunoglobulin (octanorm 16.5%) in patients with primary immunodeficiency diseases. NCT01888484. June 2018. https://clinicaltrials.gov/ct2/show/NCT01888484. Accessed April 26, 2019.
  3. McCormack PL. Immune globulin subcutaneous (human) 20% in primary immunodeficiency disorders. Drugs. 2012;72(8):1087-1097.
  4. Kobrynski L. Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases. Biologics. 2012;6:277-287.
  5. Berman K. Safety, Efficacy, Tolerability, Advantages and Disadvantages of Intravenous and Subcutaneous Immune Globulin Therapy. Highlights from IG Living Teleconference December 10, 2015. http://www.igliving.com/life-with-ig/teleconference/advantages-and-disadvantages-of-intravenous-and-subcutaneous-immune-globulin-therapy.html. Accessed April 25, 2019.
  6. Kobayashi RH, Gupta S, Melamed I, et al. Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the treatment of patients with primary immunodeficiencies. Front Immunol. 2019;10(40):1-12.